PL2989110T3 - Derywaty tamoxyfenu do leczenia chorób nowotworowych, szczególnie z wyższym poziomem białka her2 - Google Patents
Derywaty tamoxyfenu do leczenia chorób nowotworowych, szczególnie z wyższym poziomem białka her2Info
- Publication number
- PL2989110T3 PL2989110T3 PL14721738T PL14721738T PL2989110T3 PL 2989110 T3 PL2989110 T3 PL 2989110T3 PL 14721738 T PL14721738 T PL 14721738T PL 14721738 T PL14721738 T PL 14721738T PL 2989110 T3 PL2989110 T3 PL 2989110T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- protein level
- neoplastic diseases
- her2 protein
- high her2
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical class C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5456—Arylalkanephosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5449—Polyphosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
- C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/14—Styryl dyes
- C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/008—Dyes containing a substituent, which contains a silicium atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2013-308A CZ2013308A3 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
EP14721738.4A EP2989110B1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2989110T3 true PL2989110T3 (pl) | 2019-03-29 |
Family
ID=50677895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14721738T PL2989110T3 (pl) | 2013-04-24 | 2014-04-07 | Derywaty tamoxyfenu do leczenia chorób nowotworowych, szczególnie z wyższym poziomem białka her2 |
Country Status (22)
Country | Link |
---|---|
US (1) | US9896466B2 (pl) |
EP (1) | EP2989110B1 (pl) |
JP (1) | JP6375091B2 (pl) |
KR (1) | KR101764991B1 (pl) |
CN (1) | CN105452265B (pl) |
AU (1) | AU2014256546B2 (pl) |
CA (1) | CA2909994C (pl) |
CY (1) | CY1120821T1 (pl) |
DK (1) | DK2989110T3 (pl) |
EA (1) | EA029881B1 (pl) |
ES (1) | ES2699099T3 (pl) |
GE (1) | GEP20186868B (pl) |
HK (1) | HK1216317A1 (pl) |
HR (1) | HRP20181872T1 (pl) |
HU (1) | HUE042239T2 (pl) |
MD (1) | MD4626C1 (pl) |
NZ (1) | NZ713589A (pl) |
PL (1) | PL2989110T3 (pl) |
PT (1) | PT2989110T (pl) |
SI (1) | SI2989110T1 (pl) |
UA (1) | UA116469C2 (pl) |
WO (1) | WO2014173374A1 (pl) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018000306A (es) * | 2015-07-03 | 2018-03-14 | Bayer Cropscience Ag | Derivados de n-(1,3,4-oxadiazol-2-il)aril carboxamida con accion herbicida. |
CA2990985A1 (en) * | 2015-07-03 | 2017-01-12 | Bayer Cropscience Aktiengesellschaft | N-(tetrazole-5-yl)- and n-(triazole-5-yl)aryl carboxamide derivatives with herbicidal action |
EP3368011A4 (en) * | 2016-07-12 | 2019-07-10 | Accutar Biotechnology Inc. | NOVEL CONNECTIONS AND USE THEREOF |
EP3484463B1 (en) | 2016-08-19 | 2020-02-12 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
PE20200605A1 (es) | 2017-05-19 | 2020-03-10 | Lunella Biotech Inc | Antimitoscinas: inhibidores especificos de la biogenesis mitocondrial para erradicar celulas madre cancerosas |
RU2020116649A (ru) | 2017-10-24 | 2021-11-30 | Лунелла Байотек, Инк. | Митофлавосцины: нацеливание на флавин-содержащие ферменты устраняет злокачественные стволовые клетки (cscs) посредством ингибирования митохондриального дыхания |
MX2020005311A (es) | 2017-11-24 | 2020-08-17 | Lunella Biotech Inc | Compuestos de derivados de trifenilfosfonio para erradicar celulas madre cancerosas. |
EP3717015A4 (en) | 2017-12-01 | 2021-07-28 | Lunella Biotech, Inc. | REPURPOSCINS: TARGET MITOCHONDRIAL BIOGENESIS INHIBITORS TO ERADICATE CARCINOUS STEM CELLS |
US11541120B2 (en) | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
CA3085375A1 (en) | 2017-12-20 | 2019-06-27 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mdivi-1 derivatives |
CN114025769A (zh) * | 2019-04-16 | 2022-02-08 | 卢内拉生物技术有限公司 | 用于靶向线粒体和抗癌治疗的烷基-tpp化合物 |
EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1289570C (en) * | 1986-06-16 | 1991-09-24 | Tetsuji Asao | 1,1,2-triaryl-1-alkene derivatives |
CA2092996A1 (en) * | 1990-10-01 | 1992-04-02 | David Yang | High affinity tamoxifen derivatives and uses thereof |
JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
ES2541769T3 (es) * | 2003-08-22 | 2015-07-24 | Antipodean Pharmaceuticals, Inc. | Derivados de mitoquinona usados como antioxidantes dirigidos a las mitocondrias |
RU2007105138A (ru) * | 2004-07-13 | 2008-08-20 | Оридис Биомед Форшунгс-Унд Энтвиклунгс Гмбх (At) | Применение митохондриально направленного антиоксиданта при лечении болезней печени и эпителиальных раковых опухолей |
US8598145B2 (en) * | 2008-03-14 | 2013-12-03 | Stephen John Ralph | Mitochondrially delivered anti-cancer compounds |
CN102438615A (zh) * | 2009-04-17 | 2012-05-02 | 科尔比制药公司 | 包含氧化应激调节剂(osm)的药学活性组合物、新的化学实体、组合物和用途 |
WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en active Application Filing
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
- 2014-04-07 US US14/786,710 patent/US9896466B2/en active Active
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en active Active
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko active IP Right Grant
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en unknown
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro active IP Right Grant
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja active Active
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh active Active
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2016
- 2016-04-14 HK HK16104277.8A patent/HK1216317A1/zh unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
- 2018-11-08 HR HRP20181872TT patent/HRP20181872T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
NZ713589A (en) | 2017-12-22 |
KR101764991B1 (ko) | 2017-08-10 |
UA116469C2 (uk) | 2018-03-26 |
EP2989110B1 (en) | 2018-08-08 |
PT2989110T (pt) | 2018-11-15 |
DK2989110T3 (en) | 2018-12-03 |
EA029881B1 (ru) | 2018-05-31 |
MD4626B1 (ro) | 2019-04-30 |
AU2014256546A1 (en) | 2015-11-12 |
ES2699099T3 (es) | 2019-02-07 |
HUE042239T2 (hu) | 2019-06-28 |
SI2989110T1 (sl) | 2019-01-31 |
HRP20181872T1 (hr) | 2019-02-08 |
EP2989110A1 (en) | 2016-03-02 |
JP6375091B2 (ja) | 2018-08-15 |
CY1120821T1 (el) | 2019-12-11 |
HK1216317A1 (zh) | 2016-11-04 |
WO2014173374A1 (en) | 2014-10-30 |
KR20150144756A (ko) | 2015-12-28 |
MD4626C1 (ro) | 2019-11-30 |
US9896466B2 (en) | 2018-02-20 |
CA2909994A1 (en) | 2014-10-30 |
AU2014256546B2 (en) | 2017-03-30 |
CN105452265A (zh) | 2016-03-30 |
CN105452265B (zh) | 2017-05-10 |
JP2016522179A (ja) | 2016-07-28 |
US20160075726A1 (en) | 2016-03-17 |
CA2909994C (en) | 2018-06-26 |
GEP20186868B (en) | 2018-06-25 |
MD20150117A2 (ro) | 2016-08-31 |
EA201591918A1 (ru) | 2016-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181872T1 (hr) | Derivati tamoksifena za liječenje neoplastičnih bolesti, posebice s višom razinom proteina her2 | |
HK1221646A1 (zh) | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 | |
IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
EP3033079A4 (en) | Methods for the treatment of her2 amplified cancer | |
HK1213886A1 (zh) | 用於治療心血管疾病的 -哌啶- -基苯甲酰胺衍生物 | |
HK1220324A1 (zh) | 用於治療血管緊張素相關疾病的方法、化合物和組合物 | |
HK1219653A1 (zh) | 治療線粒體疾病的方法 | |
PT3089749T (pt) | Preparações combinadas para o tratamento de cancro | |
EP3007756A4 (en) | Catheter-assisted tumor treatment | |
HK1222548A1 (zh) | 治療惡性腫瘤的藥物組合 | |
EP2967062A4 (en) | DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION | |
PL2959903T3 (pl) | Lek do leczenia chorób oczu | |
GB201314386D0 (en) | Treatment system for aquaculture | |
IL244755A0 (en) | process to create xanthohumol | |
HK1223547A1 (zh) | 癌症治療方法 | |
SG11201508061UA (en) | Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency | |
EP3047857A4 (en) | Treatment for hemorrhagic diseases by anti-protein-c antibody | |
EP2976078A4 (en) | TREATMENT OF CHEMOTHERAPY-RELATED PERIPHERAL NEUROPATHY | |
EP2949329A4 (en) | THERAPEUTIC AGAINST DEMYELINISING DISEASE | |
EP3016948B8 (en) | 2-acylaminothiazoles for the treatment of cancer | |
HK1224215A1 (zh) | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 | |
GB201506512D0 (en) | Retinal sleep lamp V2 | |
TH1401005856A (th) | สารอนุพันธ์ไธอีโนไพริมิดีนชนิดใหม่, กระบวนการสำหรับการเตรียมของสารนั้น และ การใช้ในเชิงบำบัดของสารนั้น | |
GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
AU2013904239A0 (en) | Pharmaceutical combinations for the treatment of cancer |